Recombinant Human CD229/SLAMF3 Protein, CF

• Reactivity: Hu
• Applications: Binding Activity
• Format: Carrier-Free

Recombinant Human CD229/SLAMF3 Protein, CF Summary

• Details of Functionality: Measured by its ability to bind biotinylated Recombinant Human CD229/SLAMF3 in a functional ELISA. Romero, X. et al. (2005) J. Immunol. 174:7033.
• Source: Mouse myeloma cell line, NS0-derived human CD229/SLAMF3 protein
  Lys48-Lys454, with a C-terminal 10-His tag
• Accession #: Q9HBG7
• N-terminal Sequence: Lys48
• Protein/Peptide Type: Recombinant Proteins
• Gene: LY9
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Binding Activity
• Theoretical MW: 46.1 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 71-77 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CD229/SLAMF3 Protein, CF

• CD229 antigen
• CD229
• cell-surface molecule Ly-9
• hly9
• Ly9
• lymphocyte antigen 9Cell surface molecule Ly-9
• mLY9
• SLAMF3
• T-lymphocyte surface antigen Ly-9

Background

CD229, also known as Ly9 and SLAMF3, is a 120 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family (1). Mature human CD229 consists of a 407 amino acid (aa) extracellular domain (ECD) with two Ig-like V-set and two Ig-like truncated C2-set domains. It also shows a 22 aa transmembrane segment, and a 179 aa cytoplasmic domain with two immunoreceptor tyrosine-based switch motifs ITSMs (2, 3). The ECD of human CD229 shares 57% - 59% aa sequence identity with mouse and rat CD229. Within the first two Ig-like domains that are common to all SLAM proteins, human CD229 shares 24% - 39% aa sequence identity with human 2B4, BLAME, CD2F-10, CD84, CRACC, NTB-A, and SLAM. Alternate splicing generates two additional isoforms that lack the juxtamembrane Ig-like domain or short cytoplasmic region (2). CD229 is expressed on T and B cells, thymocytes, and more weakly on NK cells (2 - 6). Homophilic binding between CD229 molecules is mediated by the N-terminal Ig-like domain (7). Human and mouse CD229 exhibit cross-species binding (7). Antigen stimulation of lymphocytes induces CD229 clustering to sites of T cell - B cell contact (7). Two tyrosines in the cytoplasmic domain are required for association of CD229 with the adaptor proteins AP-2 (μ2 chain) and GRB-2 and both are required for CD229 internalization (8, 9). In addition, there are two ITSMs which mediate phosphorylation-dependent CD229 association with SAP and SHP-2 (10). These four tyrosine-containing motifs are intact in the described CD229 splice variants. CD229 knockout mice show minimally impaired immune responses, suggesting functional redundancy with other molecules (11).

1. Bhat, R. et al. (2006) J. Leukoc. Biol. 79:417.
2. de la Fuente, M.A. et al. (2001) Blood 97:3513. 
3. Sandrin, M.S. et al. (1992) J. Immunol. 149:1636.
4. Romero, X. et al. (2004) Tissue Antigens 64:132. 
5. Hogarth, P.M. et al. (1980) Immunogenetics 11:65. 
6. Mathieson, B.J. et al. (1980) J. Immunol. 125:2127.
7. Romero, X. et al. (2005) J. Immunol. 174:7033.
8. Del Valle, J.M. et al. (2003) J. Biol. Chem. 278:17430.
9. Martin, M. et al. (2005) J. Immunol. 174:5977.
10. Sayos, J. et al. (2001) Blood 97:3867.
11. Graham, D.B. et al. (2006) J. Immunol. 176:291.

Publications for CD229/SLAMF3/Lymphocyte Antigen 9 (1898-CD)(2)

Publications using 1898-CD

• SV Radhakrish, T Luetkens, SD Scherer, P Davis, ER Vander Mau, ML Olson, S Yousef, J Panse, Y Abdiche, KD Li, RR Miles, W Matsui, AL Welm, D Atanackovi CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide Nat Commun, 2020-02-07;11(1):798. 2020-02-07 [PMID: 32034142] (Bioassay, Surface Plasmon Resonance (SPR, Human)
• The extracellular interactome of the human adenovirus family reveals diverse strategies for immunomodulation Nat Commun, 2016-05-05;7(0):11473. 2016-05-05 [PMID: 27145901] (Human)

Bioinformatics

• Gene Symbol: LY9
• Uniprot:
  • Q9HBG7()